Wednesday, June 12, 2024

Exploring Mining Podcast - Peter Krauth Answers Who, What, Where in Silver? @peter_krauth



 

Exploring Mining Podcast - Peter Krauth Answers Who, What, Where in Silver?  @peter_krauth

 

Gain insight to when we might see a $30 floor on Silver, and what Silver Juniors the Big Players are buying 

June 12, 2024 Investorideas.com, a global investor news source covering mining and metals stocks releases today’s edition of Exploring Mining Podcast, featuring another special  edition interview with well-known Silver expert Peter Krauth.

Peter is the author of the bestselling book The Great Silver Bull. Peter is a frequent guest speaker on Silver at many mining events around the world, and an expert in precious metals markets. He runs the silver-focused investment newsletter Silver Stock Investor (www.silverstockinvestor.com).

In this episode, host Cali Van Zant follows up on their conversation in March. Peter gives his forecast for when we might see a $30 floor on silver, key drivers to pay attention including China buying silver at premium prices, and rate cuts effecting markets.

Peter also speaks about his new transition to working with Jeff Clark and the GoldAdvisor.com . He also discusses some of the companies he covers in his newsletter and who is worth taking a look at.

Companies discussed in this podcast include Summa Silver Corp. (TSXV: SSVR), Sun Silver, Kootenay Silver Inc. (TSXV: KTN), GR Silver Mining Ltd. (TSXV: GRSL) and more

 

To hear about the other juniors and more expert advice take a listen to the podcast below

 

Listen to the podcast:

https://www.spreaker.com/episode/exploring-mining-peter-krauth-answers-who-what-where-in-silver--60357731

 

Watch on YouTube

https://youtu.be/mKWv5bWD6j8

 


Read this in full at https://www.investorideas.com/news/2024/exploring-mining/06121Peter-Krauth.asp

 

Listen to Exploring Mining podcast on iTunes Apple podcasts   

 

Listen to Exploring Mining on Spotify

 

About Peter Krauth, and Silver Stock Investor Newsletter

Peter Krauth has been investing and writing about silver for more than 20 years.

As a precious metals expert and former portfolio adviser, Peter is a frequent contributor to financial websites such as Kitco, Forbes, Seeking Alpha, BNNBloomberg, and Financial Post. Peter is also a regular presenter at investment conferences, such as the MoneyShow and Metals Investor Forum. He uses his extensive network to uncover outstanding opportunities.

 

He is the author of the bestselling book The Great Silver Bull, which details silver’s historical role as money, why it is critical in technology, and how to build your silver investment portfolio to dramatically outperform inflation

https://silverstockinvestor.com/

X @peter_krauth

 

The Investorideas.com podcasts are also available on Apple Podcasts, Audible, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Podcasts and most audio platforms available.

 

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

 

Research mining stocks at Investorideas.com with our free mining stocks directory at Investorideas.com https://www.investorideas.com/Gold_Stocks/Stocks_List.asp 

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas @Exploringmining

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be a guest or sponsor this podcast

800-665-0411

 

 


Get more mining stock investor ideas- news, articles, podcasts and stock directories

 

 

Tuesday, June 11, 2024

Breaking Cleantech Stock News: dynaCERT (TSX: $DYA.TO) (OTCQX: $DYFSF) Acquires a 15% Ownership of Cipher Neutron; @dynaCERT

Breaking Cleantech Stock News: dynaCERT (TSX: $DYA.TO) (OTCQX: $DYFSF) Acquires a 15% Ownership of Cipher Neutron; @dynaCERT

 


 

TORONTO, ON - June 11, 2024 (Investorideas.com Newswire) dynaCERT Inc. (TSX: DYA) (OTCQX: DYFSF) (FRA: DMJ) ("dynaCERT" or the "Company") is pleased to announce an initial acquisition totalling fifteen percent (15%) of Cipher Neutron Inc. ("Cipher Neutron" or "CN").

 

dynaCERT has agreed to receive 7,178,000 Units of equity of Cipher Neutron, each Unit consisting of one (1) Class A Share in the capital of Cipher Neutron and one half (1/2) of a Class A Share Purchase Warrant. This acquisition totals 7,178,000 Class A Shares in the capital of the Cipher Neutron and 3,589,000 Class A Share Purchase Warrants, representing fifteen percent (15%) of the common shares of Cipher Neutron on an undiluted basis and over twenty percent (20%) of Cipher Neutron on a fully diluted basis.

 

This acquisition marks dynaCERT's initial equity participation in Cipher Neutron and paves the way for the potential acquisition of additional shares through further investments such as the exercise of Class A Share Purchase Warrants.

 

As consideration for dynaCERT's subscription of equity in Cipher Neutron, the collaboration agreement dated February 17, 2023 and the amendment thereto dated June 28, 2023 between Cipher Neutron and dynaCERT have been terminated by mutual consent of all parties and options under this agreement have been cancelled.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of dynaCERT Inc.

 

Read this news, featuring DYA in full at  https://www.investorideas.com/news/2024/06111DYA-Acquires-Ownership-of-Cipher-Neutron.asp

 

Cipher Neutron's Industry Leadership

Cipher Neutron is a leader in the AEM (Anion Exchange Membrane) electrolysis business, known by industry participants for its cutting-edge technology and remarkable innovation in the sector. Over the past years, Cipher Neutron has achieved significant milestones, including the successful shipment of one of the world's largest AEM electrolyser single stacks. Additionally, CN is on track to develop a 250 kW AEM electrolyser stack, which will be the largest in the world.

 

Furthermore, Cipher Neutron has secured undiluted funding from prestigious government organizations such as the Independent Electricity System Operator (IESO) and Alberta Innovates. This substantial government support underscores the immeasurable potential of Cipher Neutron's groundbreaking technology. With upcoming projects ranging from small Megawatt scale to hundreds of Megawatts, Cipher Neutron has positioned itself as an exceptional investment opportunity.

 

Cipher Neutron's AEM technology is PFAS-free (free of harmful chemicals) and does not require Platinum Group metals to manufacture, ensuring it is both environmentally friendly and cost-effective. Cipher Neutron's scalable and highly efficient AEM electrolysis system offers lower CAPEX and OPEX, making it one of the most sustainable and affordable electrolysers for producing Green Hydrogen.

 

The Green Hydrogen Market

The Green Hydrogen market has been projected to exceed $500 billion by 2030, driven by a global push towards sustainable energy solutions and the decarbonization of industries. As major global economies increasingly invest in green hydrogen, recognizing its potential to reduce greenhouse gas emissions and provide a reliable, renewable energy source, the timing of dynaCERT's strategic equity acquisition is opportune.

 

By acquiring equity in Cipher Neutron, dynaCERT significantly strengthens its strategic position while adding considerable value potential to its shareholders. This equity acquisition aligns seamlessly with dynaCERT's vision of leveraging high-potential growth businesses to enhance shareholder value. dynaCERT has always believed in the transformative potential of Green Hydrogen, and this equity acquisition represents a prime opportunity to diversify the Company's portfolio and support innovative technologies that contribute to a greener future.

This strategic move reaffirms dynaCERT's unwavering commitment to expanding its footprint in innovative and high-growth sectors, providing dynaCERT's shareholders with promising new opportunities, and reinforcing the Company's market position through valuable equity investments.

 

Jean-Pierre Colin, Executive Vice President, CFO & Corporate Secretary & Director of dynaCERT and Director & Corporate Secretary of Cipher Neutron, stated, "I congratulate both Cipher Neutron and dynaCERT for reaching this mutually beneficial agreement after years of friendly negotiations. As well, for dynaCERT shareholders, the benefit of equity ownership in Cipher Neutron is now unequivocably established; it sets up dynaCERT to benefit from the cherished upside potential of Cipher Neutron and removes any uncertainty regarding dynaCERT's ownership participation in Cipher Neutron."

 

Gurjant Randhawa, President and CEO of Cipher Neutron, stated, "Cipher Neutron is pleased to welcome dynaCERT as a new shareholder and appreciates their support of our innovative AEM Electrolyser technology. As a global leader in Green Hydrogen Electrolysers, we have always enjoyed a strong working relationship with dynaCERT and commend them for their continued commitment. By aligning with Cipher Neutron that offers cutting-edge innovation and sustainable technology, we believe this equity participation by dynaCERT can provide the prospect of significant potential and the unusual exposure to a market that offers considerable rapid growth."

 

Jim Payne, Chairman and CEO of dynaCERT, stated, "Our stated mission of being a global leader in the New Hydrogen Economy is significantly advanced by our strategic equity participation in a rapidly expanding enterprise like Cipher Neutron. dynaCERT's ownership stake in Cipher Neutron, an AEM electrolyser leader, offers a promising opportunity in North American public markets and provides the unique exposure in the global growth of green hydrogen. This substantial equity interest in Cipher Neutron positions dynaCERT with the advantages to leverage this growth asset and enhance corporate value, designed for the benefit of all our shareholders."

 

About Cipher Neutron Inc.

Cipher Neutron is a rapidly growing disruptive technology company focused on AEM Electrolysers for Green Hydrogen production and Reversible Fuel Cells for power generation and Energy Storage Solutions. Cipher Neutron is a global group of scientists, engineers, technology developers, experts in hydrogen technology, investment bankers and people that have worked in hydrogen for decades. Cipher Neutron's innovative products, such as AEM Electrolysers and Reversible Fuel Cells have unique advantages over other Green Hydrogen production, power generation and energy storage solutions currently available in the global market. Please see: www.cipherneutron.com.

 

About dynaCERT Inc.

dynaCERT Inc. manufactures and distributes Carbon Emission Reduction Technology along with its proprietary HydraLytica™ Telematics, a means of monitoring fuel consumption and calculating GHG emissions savings designed for the tracking of possible future Carbon Credits for use with internal combustion engines. As part of the growing global hydrogen economy, our patented technology creates hydrogen and oxygen on-demand through a unique electrolysis system and supplies these gases through the air intake to enhance combustion, which has shown to lower carbon emissions and improve fuel efficiency. Our technology is designed for use with many types and sizes of diesel engines used in on-road vehicles, reefer trailers, off-road construction, power generation, mining and forestry equipment. Website: www.dynaCERT.com.

 

READER ADVISORY

Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. In particular, information relating to Cipher Neutron Inc., AEM Electrolysers, the green hydrogen markets and dynaCERT Inc.’s investment in Cipher Neutron Inc. and its potential cannot be independently verified. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance of achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Forward-looking information is based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; the uncertainty of the emerging hydrogen economy; including the hydrogen economy moving at a pace not anticipated; our ability to secure and maintain strategic relationships and distribution agreements; and the other risk factors disclosed under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

 

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of the release.

 

On Behalf of the Board
Murray James Payne, CEO

 

Contacts

For more information:
Jim Payne, CEO & President
dynaCERT Inc.
#101 - 501 Alliance Avenue
Toronto, Ontario M6N 2J1
+1 (416) 766-9691 x 2
jpayne@dynaCERT.com

 

Investor Relations
dynaCERT Inc.
Nancy Massicotte
+1 (416) 766-9691 x 1
nmassicotte@dynaCERT.com

 

Gurjant Randhawa, CEO & President
Cipher Neutron Inc.
101 - 501 Alliance Avenue
Toronto, Ontario M6N 2J1
+1 (647) 803-0002
grandhawa@cipherneutron.com

 

dynaCERT Inc. (TSX:DYA.TO) (DYFSF) is a featured Renewable Energy / Fuel Cell stock on Investorideas.com

 

Visit profile page

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. contact management and IR of each company directly regarding specific questions. Disclosure. DYA is a monthly featured cleantech stock on Investorideas.com effective March 1, 2024 for 6 months. (equivalent of 3500 month in stock) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 



Get more Renewable Energy Stock news, articles, podcasts and Stock Directories

 

Monday, June 10, 2024

Exploring Mining Podcast with Chris Timmins of Pegasus Resources Inc. (TSXV: PEGA) (OTCQB: SLTFF) update with historic drilling data; @pegasusresinc

Exploring Mining Podcast with Chris Timmins of Pegasus Resources Inc. (TSXV: PEGA) (OTCQB: SLTFF) update with historic drilling data; @pegasusresinc

 

CEO Chris Timmins Discusses Latest press release on Historic data and Upcoming drill program for Energy Sands Project

 



 

June 8, 2024 (Investorideas.com Newswire) Investorideas.com, a global investor news source covering mining and metals stocks releases today's Exploring Mining Podcast, featuring a follow-up interview with Chris Timmins, CEO and President of Pegasus Resources Inc. (TSXV: PEGA) (OTCQB: SLTFF).

 

Listen to the podcast on Investorideas.com

https://www.investorideas.com/Audio/Podcasts/2024/060824-Mining.mp3

 

Watch the episode on YouTube:

https://www.youtube.com/watch?v=AHdD1ERvCdw



Listen to Exploring Mining podcast on iTunes Apple podcasts

 

Listen to Exploring Mining on Spotify

 

Paid dissemination on behalf of Pegasus Resources Inc.

 

In this episode, host Cali Van Zant talks to Chris Timmins about the historic data acquired, and consistencies and trends on their Energy Sands project (Full company press release here). Chris discusses what this means for permitting and updated targets for drilling this summer.

 

Read this in full at https://www.investorideas.com/news/2024/exploring-mining/06081Chris-Timmins-of-Pegasus-Resources-PEGA.asp

 




Full company press release https://www.pegasusresourcesinc.com/latest

 

About Pegasus Resources Inc

Pegasus Resources Inc. is a diversified Junior Canadian Mineral Exploration Company with a focus on uranium, gold, and base metal properties in North America. The Company is also actively pursuing the right opportunity in other resources to enhance shareholder value. For additional information, please visit the Company at www.pegasusresourcesinc.com

 

About the Energy Sands Project

The Energy Sands project consists of 100% owned 78 lode claims covering 1,560 acres in the San Rafael Uranium District of Utah approximately 4 kilometres from the San Rafael Uranium Project of Western Uranium and Vanadium.

 

Utah is ranked among the top 5 most favorable jurisdictions in the United States and is home to two built uranium mills and a third soon to be built by Western Uranium and Vanadium, which gives the companies operating in the area an exceptional advantage for future ore processing for conventional mining projects.

 

  • Historical small-scale production, between 1953 and 1956, totaling 103,600 Pounds at a grade of 0.373% U3O8 and 1.10% V2O5.
  • 4 Corners Mines road runs through the property and connects to Interstate 70 (less 2km away), a mainline route of the Interstate Highway System in the United States connecting Utah and Maryland.

 

https://www.pegasusresourcesinc.com/energysands

 

Check out Pegasus Resources profile page on InvestorIdeas

https://www.investorideas.com/CO/PEGA/

 

The Investorideas.com podcasts are also available on Apple Podcasts, Audible, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Podcasts and most audio platforms available.

 

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

 

Research mining stocks at Investorideas.com with our mining stocks directory at Investorideas.com https://www.investorideas.com/Gold_Stocks/Stocks_List.asp

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.

 

Disclaimer/Disclosure: Pegasus Resources Inc. is a paid featured mining stock on Investorideas.com Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions. Pegasus Resources Inc. is a paid featured mining stock on Investorideas.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be a guest or sponsor this podcast

800-665-0411

 



Get more mining stock investor ideas- news, articles, podcasts and stock directories

 

Virus Treatments as Bird Flu Make Headlines (NASDAQ: $AEMD) (NASDAQ: $MRNA) (NYSE: $PFE) (NASDAQ: $IBRX) (NASDAQ: $ALGS) @moderna_tx @pfizer @ImmunityBio @AligosThera

Virus Treatments as Bird Flu Make Headlines (NASDAQ: $AEMD) (NASDAQ: $MRNA) (NYSE: $PFE) (NASDAQ: $IBRX) (NASDAQ: $ALGS) @moderna_tx @pfizer @ImmunityBio @AligosThera

 

June 10, 2024 - Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of viruses, featuring Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

 

The threat of viruses is back in the news with multiple news sources, including the Guardian reporting, ”The World Health Organization (WHO) has said a man’s death in Mexico was caused by a strain of bird flu called H5N2 that has never before been found in a human.”

 

The WHO said Wednesday it wasn’t clear how the person became infected. “Although the source of exposure to the virus in this case is currently unknown, A (H5N2) viruses have been reported in poultry in Mexico,” it said in a statement.

 

Continued: “Scientists are on alert for changes in the virus that could signal that bird flu is adapting to spread more easily among humans.

 

Continued:  “But the UN agency said Wednesday said the current risk of the bird flu virus to the general population in Mexico is low.”

 

With global populations and economies still feeling the impact of Covid-19, any virus threat is going to make headlines.

 

As viruses make headlines, companies are seeking solutions and not all are focused on vaccine development.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of Aethlon Medical Inc.

 

Read this article featuring AEMD in full at  https://www.investorideas.com/news/2024/biotech/06101Virus-Treatments-Bird-Flu.asp

 

Aethlon Medical, Inc. (Nasdaq: AEMD) just recently announced an update on its technology for cancer treatment on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.

 

The Aethlon Hemopurifier® technology is designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a “Breakthrough Device” for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and life-threatening viruses that are not addressed with approved therapies.

 

As reported previously, separate from its current focus on cancer treatment, Aethlon has investigated the potential for the use of the Hemopurifier® in viral diseases.

 

According to their SEC filing, “We also believe the Hemopurifier can be part of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals infected with human immunodeficiency virus, or HIV, hepatitis-C and Ebola.”

 

“Additionally, in vitro, the Hemopurifier has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, Monkeypox virus and the reconstructed Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-government research institutes.”

 

Recently, Zacks reported that “Vaccine Stocks Rise on Growing Threat of Bird Flu Infections”

 

“Shares of several vaccine makers soared after reports suggest that the Biden administration is in discussions with Moderna (NASDAQ: MRNA) and Pfizer (NYSE:PFE) to set up a possible vaccine program aimed at preventing the spread of the H5N1 virus, also known as bird flu, in humans.”

 

Continued: “These reports came to light after the discovery of two cases of H5N1 virus in dairy farm workers in Texas and Michigan this year. Both these workers experienced symptoms in the eye after coming into contact with dairy cows infected with the H5N1 virus.”

 

But the treatment of viral diseases has other options including immunotherapy.

 

ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced earlier this year the publication of preclinical data in the online issue of Science, First Release indicating that combination therapy with N-803, an IL-15 superagonist, and broadly neutralizing antibodies may potentially enable the immune system to manage human immunodeficiency virus (HIV) without the need for antiretroviral treatment.

 

From the news: In the preclinical non-human primate study, researchers led by Dr. James Whitney, Ph.D. and funded by the National Institutes of Health and the National Institute of Allergy and Infectious Diseases (NIAID) demonstrated that using N-803, in combination with broadly neutralizing antibodies (bNAbs), led to sustained viral control after discontinuation of antiretroviral therapy (ART) in ART-suppressed rhesus macaques infected with simian-human immunodeficiency virus AD8 (SHIV-AD8). Treatment with N-803 and bNAbs led to immune activation and transient viremia, but only limited reductions in the SHIV reservoir. Upon ART discontinuation, all animals experienced viral rebound, followed by long-term virus control for up to 10 months in approximately 70% of those treated with N-803 and bNAbs.

 

"The viral reservoir in people with HIV is established within the first few days of infection and cannot be eliminated by the body’s immune system or currently available treatments, representing a significant obstacle in curing an established HIV infection," said James B. Whitney, M.D., Study Author and Researcher at the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and Harvard Medical School. "When combined with broadly neutralizing antibodies, N-803 has the potential to provide viral control without significant reduction in the viral reservoir, which further suggests that the complete eradication of this reservoir may not be required to induce sustained remission after discontinuing antiretroviral therapy."

 

Taking another approach to viral diseases, Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best-in-class therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.

 

The Company just announced positive data from six poster presentations at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.

 

From the news: Reported for the first time were antiviral and safety data in HBeAg-negative CHB subjects who received a daily single dose of 300 mg ALG-000184 monotherapy for ≤60 weeks. In all 11 subjects (100%), complete suppression of HBV DNA (<LLOQ 10 IU/mL) and RNA (<LLOQ 10 copies/mL) were noted, with reduction in HBcrAg levels indicating inhibition of HBV replication, as well as inhibition of cccDNA establishment/replenishment. In both patient populations, ALG-000184 continues to be well tolerated with no viral breakthrough.

 

With bird flu cases on the rise, retail investors are once again on the hunt for stocks with potential solutions.

 

As Bloomberg reported recently,”Mounting cases of bird flu in humans is luring the day trading crowd to snap up stock in vaccine developers. It’s a familiar setup for industry veterans who have witnessed past trading frenzies at the first signs of an outbreak.”

 

This won’t be the last viral outbreak. There are more viruses than stars in the universe. And there are multiple solutions to treating viruses in addition to vaccines.

 

Read part one of the series at Investorideas.com

https://www.investorideas.com/news/2024/biotech/06031Blood-Purification-Medical-Devices.asp

 

Research biotech and medical device/ tech stocks at Investorideas.com

https://www.investorideas.com/BIS/Stock_List.asp


About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: This news article featuring AEMD is a paid for news release on Investorideas.com.  AEMD is a paid featured medical tech stock on our site. Our site does not make recommendations for purchases or sale of stocks, services or products.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories